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Renal allograft survival following acute rejection correlates It has been well established that acute rejection (AR)
with blood pressure levels and histopathology. is a strong predictor of renal allograft survival [1–3]. In
Background. Acute rejection (AR) is a strong predictor of addition, several studies have identified other factorsrenal graft survival, but the negative impact of AR on survival
that appear to modulate the negative impact of AR onis variable, suggesting that other factors modulate this relation-
graft survival. For example, (a) in general, the later theship. In this study, we examined the variables that correlate
with graft survival after AR, particularly the impact of blood AR occurs following transplantation, the more detrimen-
pressure (BP), graft function, and histopathology. tal is its effect on graft survival [4, 5]. (b) Increasing
Methods. The study population included patients with no numbers of AR episodes, even if they occur early afterAR (N 5 942) and patients with one (N 5 407) or two (N 5
the transplant, increase the risk of graft loss [2]. (c) Graft156) AR during the first year post-transplant. Patients were
dysfunction after AR is also an important variable thatadults who were recipients of living related (LRD, N 5 410)
or cadaveric grafts (CAD, N 5 1095) and who were trans- modulates the impact of AR on graft survival [6]. (d)
planted in a single institution and followed for 5.8 6 4 years. Finally, the histopathological grade of the AR episode
Results. Compared with patients without AR, those with
appears to correlate with graft prognosis [7, 8].AR were significantly younger, had more human lymphocyte
Recent advances in immunosuppression have causedantigen mismatches, and included more CAD recipients. Graft
survival was analyzed beyond six-months post-transplant. In a significant reduction in the number of patients who
patients with AR, reduced survival correlated (multivariate) have AR following transplantation [9, 10]. However, the
with (a) younger recipients (P 5 0.01), (b) AR occurring later numbers of patients with AR is considerable, and theduring the first-year post-transplant (P 5 0.0006), (c) elevated
factors that determine the lower long-term graft survivalserum creatinine (Cr) before (P 5 0.05), at the time (P 5
in these individuals remain unclear. The ultimate goal0.0001) of, or after AR (P 5 0.0004), and (d) average BP levels
after AR [systolic BP (P 5 0.003 logistic, P , 0.0001 by Cox), of these studies is to identify variables that are associated
diastolic BP (P 5 0.007), mean arterial pressure (P , 0.0001)]. with shortened graft survival after AR. Ultimately, we
This latter correlation was independent of graft function and would like to determine whether modification of thoserecipient race. Thus, post-AR BP levels correlated with graft
variables alters the prognosis of patients with AR. In thissurvival in patients with post-AR creatinine #2 mg/dl (N 5
study, we sought to determine the relationship between408, P 5 0.0009), in Caucasian recipients (P 5 0.001), and in
African American recipients (P 5 0.01). In contrast, there was graft survival, AR, and graft function. Furthermore,
no significant correlation between BP levels and graft survival these variables were analyzed in the context of other
in patients without AR. AR histopathology, analyzed in pa- covariates shown to correlate with graft survival, includ-tients with one AR episode, correlated with graft survival only
ing blood pressure (BP) levels and the histopathologythe first six months after AR but not thereafter.
of AR. Regarding BP, in previous studies, we showedConclusions. Graft survival after AR can be predicted inde-
pendently by graft function and BP levels after the event. that poorly controlled BP correlates with renal allograft
Patients with elevated BP post-AR have poor graft survival survival in African Americans but not in Caucasian ca-
even if they have excellent graft function.
daveric graft (CAD) recipients [2]. Other studies had
shown previously a relationship between hypertension
and graft survival in other patient populations [11, 12],Key words: graft survival, transplantation, renal allograft, hyper-
tension. and a more recent analysis of a large number of renal
allograft recipients confirmed that elevated BP levels
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that correlate with BP, principally race and graft func- 69% corticosteroid and antilymphocyte antibody) or vas-
cular AR (24% corticosteroid; 76% corticosteroid andtion, are also determinants of graft survival. Based on
these considerations, one of the goals of our study was antibody), reflecting our aggressive approach to the
treatment of ARs.to determine whether there is in fact a correlation be-
tween BP and graft survival that is independent of other
Clinical parametersvariables. To evaluate the relationship between histopa-
thology and graft survival, we used the Banff criteria, For this analysis, clinical values were analyzed as fol-
lows: (a) The pre-AR creatinine (pre-Cr) was definedwhich allows a consistent grading of the histopathology
of AR [14]. Because of its initial description, these histo- as the lowest serum creatinine concentration within one
month prior to the AR episode. (b) The post-AR creati-pathological criteria have been shown to correlate with
the acute changes in serum creatinine that occur during nine (post-Cr) was defined as the lowest serum creatinine
concentration more than one month and less than threeAR and perhaps also with long-term survival [7, 8]. How-
ever, the relationship between histopathology and graft months post-AR. (c) Peak-Cr was the higher concentra-
tion of serum creatinine within one month of the diagno-survival has not been analyzed together with other clini-
cal parameters that determine graft prognosis. sis of AR. (d) The pre-AR BP (pre-BP) was the average
systolic, diastolic, or mean artery pressure (MAP) fromThe criteria used here for the selection of a study
population were designed to minimize the impact of time the time of transplantation to the time of diagnosis of
AR. (e) The post-AR BP (post-BP) was the averageof AR and number of AR on graft survival. Thus, this
study includes renal allograft recipients who had no AR systolic, diastolic, or MAP BP level achieved on the
patient from two months following AR to the end ofor who had one or two AR episodes during the first-
year post-transplant. the follow-up period. BP levels were determined by the
patient at home and during outpatient clinic visits. Prior
to AR, a total of 69,622 BP readings was analyzed, and
METHODS
every patient had a minimum of 10 BP readings recorded.
Study population Following AR, a total of 51,106 BP levels were analyzed.
A significant higher number of BP recordings were avail-Included are all adult kidney transplant recipients
done at The Ohio State University from September 26, able in patients who had AR (47 per patient) than in
patients who did not have AR (25 per patient), most1982, to June 14, 1996, who additionally met the follow-
ing criteria: (a) Patients had no AR episodes any time likely reflecting the closer clinical follow-up of patients
considered to be at higher risk. Post-transplant acutepost-transplant (N 5 942), or (b) patients had one (N 5
407) or two (N 5 156) AR episodes during the first-year tubular necrosis (ATN) was defined as the need for dial-
ysis during the transplant admission.post-transplant. Patients with more than two ARs and/or
with AR episodes beyond the first year post-transplant For histopathological assessment, all of the biopsies
that the patient had at the time of AR were reviewedwere excluded from the study. Patients included 1095
recipients of CAD and 410 recipients of grafts from living by one or two of the authors (D.D.S., F.G.C.). Only those
biopsies that had less than moderate chronic allograftdonors (LRD).
The majority of patients received induction immuno- nephropathy (CN; such as interstitial fibrosis and tubular
atrophy) [14] were included, because it was consideredsuppression immediately post-transplant, which consisted
of polyclonal (Minnesota ALG) or monoclonal antilym- that the presence of moderate to severe CN would ob-
scure the interpretation of the analysis of the impactphocyte antibodies (OKT3; Ortho Biotech, Raritan, NJ,
USA) until the serum creatinine was #2.5 mg/dl when of acute pathological changes on graft survival. Twenty
patients had moderate to severe CN, and these patientscyclosporine was initiated. Maintenance immunosuppres-
sion consisted of triple immunosuppression with predni- were not included in this analysis. In addition, in this
portion of the study, only those patients who had onesone, azathioprine, and cyclosporine until 1995 when
azathioprine was replaced by mycophenolate mofetil AR episode were included, because in patients with two
AR episodes, it was difficult to determine whether the(CellCept) at a dose of 2 to 3 g/day.
The diagnosis of AR was based on both clinical and histopathology of the first or the second AR episode had
an impact on graft survival. AR intensity was gradedpathological information. When AR was suspected clini-
cally, the patient was admitted to the hospital and had according to the Banff criteria [14] with two modifica-
tions: (a) Patients with allograft infarction were classifiedan allograft biopsy done soon after admission before or
simultaneously with the initiation of anti-AR therapy. separately from patients with grade III or severe rejec-
tion. This was done because we showed previously thatARs were treated with corticosteroid only or in combina-
tion with an antilymphocyte antibody preparation. These these two groups of patients have significantly different
graft survival [15]. (b) Patients with moderate vasculartwo forms of AR treatment were used with similar fre-
quency in nonvascular AR (31% corticosteroid alone; rejection (Banff grade IIB) were analyzed together with
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Table 1. Characteristics of the patient population AR and in 93% of patients with two AR, the episode
occurred during the first three months post-transplant.Variables No AR AR P
Donor age 33615a 32615
Graft and patient survivalDonor race % Caucasians 88% 85%
Donor gender % males 43% 42% After an average follow-up of 5.8 6 4 years, 26% of
Donor origin % LRD 30% 24% 0.0001b
patients without AR died compared with 25 and 27%Recipient age 43615 41614 0.005c
Recipient race % Caucasians 83% 82% among patients who had one or two AR episodes, respec-
Recipient gender % males 61% 60% tively. Graft survival was not significantly different be-
HLA mismatches (A 1B1D) 3.861.8 4.261.7 0.002d
tween patients with one (25% grafts lost) or two ARPeak PRAe 7.2618 10.2623
Pre PRA 6.3616 9.2621 episodes (30%, P 5 0.2). However, graft survival in pa-
Pre-Cr mg/dl f 1.861.4 1.861 tients with one or two AR episodes was significantly
Post-transplant ATN 7% 10% 0.02b
worse than in patients without AR (11% grafts lost, chi-
a Values represent mean and standard deviations square analysis, P , 0.0001). By Cox regression, graftb chi square
c t-test survival time was not different in patients who had one
d Mann–Whitney; P 5 0.016 when the analysis included only CAD transplant or two AR episodes (Fig. 1), but graft survival in theserecipients
e PRA, panel reactive antibodies two groups of patients was significantly different from
f In patients without AR the pre-Cr represent mean of values during the six that of patients without AR episodes.months post-transplant
Correlates of long-term graft survival in patients with
acute rejection
Table 2 displays the variables that correlate signifi-patients with severe rejection (Banff grade III) because
the prognosis of these two groups of patients is similar. cantly with graft survival beyond six-months post-trans-
plantation in patients with AR. As can be seen by univar-For statistical analysis, the histopathological grade of
AR was given a numerical value as follows: 1 5 border- iate analysis, the following variables correlated with
worse long-term graft survival: (a) younger recipientsline AR (N 5 37); 2 5 grade I (N 5 78); 3 5 grade IIA
(N 5 42); 4 5 grades IIB and III (N 5 72); 5 5 infarcts [2], (b) AR occurring later post-transplant, such that
increasing time post-transplant when the AR occurs is(N 5 16). All biopsies were reviewed without the knowl-
edge of the ultimate fate of the allograft. associated with progressively worse prognosis, (c) higher
levels of serum creatinine concentration before (pre-Cr),
Analysis of the data during (peak-Cr), or after the AR episode (post-Cr).
The correlation between pre-Cr and graft survival wasData throughout the manuscript are expressed as
mean 6 sd of the mean. Values were compared by Stu- also significant when patients with post-transplant ATN
were excluded from the analysis. (d) Higher levels of BPdent’s t-test or by nonparametric tests if the values were
not normally distributed. Proportions were compared by after AR (post-BP) was also a correlate. The relationship
between post-BP and graft survival was significant forchi-square analysis. Graft survival was censored at the
time of patient death and analyzed by Kaplan–Meier systolic BP (P 5 0.003, logistic regression), diastolic BP
(P 5 0.007), and MAP (P , 0.0001). By multivariateplots and Cox regression. Correlations between graft
survival and other variables were calculated by logistic analysis (Table 2), recipient age, time of the AR, graft
function, particularly after AR, and post-BP levels corre-regression analysis.
lated with graft survival.
When the analysis above was calculated considering
RESULTS
graft survival time as the dependent variable, the results
Characteristics of the patient population were similar. Thus, shorter graft survival time correlated
by both univariate and multivariate Cox analysis withTable 1 displays these data. Compared to patients
without AR, patients with AR were significantly younger (a) AR that occurred late during the first year post-
transplant (P , 0.0001), (b) serum creatinine level pre-AR(P 5 0.005), included a significantly higher number of
CAD transplants (P 5 0.0001), and had a significantly (,0.00001), peak-Cr (P , 0.0001) or post-Cr (P , 0.0001),
and (c) post-BP (P , 0.0001, multivariate analysis).higher number of human lymphocyte antigen (HLA)
mismatches (P 5 0.002 for the whole group, P 5 0.01 The histopathological grade of the AR episode, ana-
lyzed in patients with one AR episode, did not correlatefor CAD). The prevalence of post-transplant ATN was
low, but it was significantly higher in patients with AR with long-term allograft survival. In addition, the follow-
ing variables did not correlate significantly with graft(10%) than in patients without AR (7%, P 5 0.02). In
contrast, there were no significant differences between survival: donor and recipient variables (race, age, and
gender), HLA matching, plasma renin activity reactivity,patients with or without AR in donor, recipient variables,
or pre-AR graft function. In 95% of patients with one origin of the graft (LRD vs. CAD), and number of AR
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Fig. 1. Kaplan–Meier plots of death censored
graft survival in patients without acute rejec-
tion (AR; - - -), patients with one (—) and
patients with two AR episodes (—; P , 0.0001
by Cox regression, indicating a significant dif-
ference between graft survival between both
groups of patients with AR and patients with-
out AR).
Table 2. Correlations between graft survival beyond 6 months post- Blood pressure, graft function, and long-term graft
transplant and clinical parameters in patient with AR
survival after acute rejection
Multivariate analysisa
Univariate The results of the multivariate analysis displayed ear-
Parameters analysis Pre-Cr Peak-Cr Post-Cr lier in this article indicate that the relationship between
Recipient age 0.04b 0.01 0.01 0.004 graft survival and post-BP is statistically independent
Time of AR ,0.0001 0.0006 ,0.0001 0.001 from graft function. However, post-BP and post-Cr cor-Pre-Cr 0.002 0.05 — —
relate significantly with each other (r 5 0.21, P , 0.0001Peak-Cr during AR ,0.0001 — 0.0001 —
Post-Cr ,0.0001 — — 0.0004 by Spearman), suggesting that there is an interdepen-
Post-BP (MAP) ,0.0001 0.0005 0.0002 0.0005 dence between the impact of graft function and BP on
a Because all of the values of serum creatinine are related to each other, the graft survival. To assess these relationships further, wepre-Cr, the peak-Cr and the post-Cr values were analyzed in separate multivariate
models re-analyzed graft survival after AR selecting only those
b Logistic regression analysis patients who had a post-Cr #2 mg/dl (N 5 408).
By multivariate analysis (logistic regression), the follow-
ing variables correlated with worse graft survival: (a)
younger recipient (P 5 0.003), (b) elevated post-AR BPepisodes. Of interest, BP levels before the AR episode
(systolic BP, P 5 0.0009; MAP, P 5 0.003), and (c)did not correlate with graft survival after AR. Post-BP
increasing time post-transplant (P 5 0.02), such that thelevels were significantly lower than pre-BP levels (post-
graft prognosis progressively worsens as the time post-systolic BP, 138 6 13 mm Hg; pre-BP, 149 6 14, paired t,
transplant when the AR occurs increases. In this sub-P , 0.0001) in both patients who eventually lost their
group of patients, the post-Cr concentration did not cor-graft and those that retained the graft. This reduction in
relate with graft survival. Figure 2 graphically displaysBP was most likely the result of a significant increase in
the relationship between average systolic BP levels post-the number of BP medications following AR (number
AR and graft survival in the subgroup of patients withof anti-BP medication/patient: pre-AR 2.06 6 1; post-AR,
post-Cr #2 mg/dl. As can be seen, progressive increases2.6 6 1.2, paired t, P , 0.0001). The number of BP
in post-systolic BP, beyond 130 mm Hg, were associatedmedications and the class were not significantly different
with progressive declines in graft survival. It should bein patients with or without eventual graft loss. Post-BP
noted that the serum creatinine concentration was notlevels did not correlate significantly with the cumulative
significantly different among the groups of patients dis-dose of prednisone or cyclosporine A during the year
following the AR episode. played in Figure 2: SBP , 130 (1.5 6 0.5 mg/dl, N 5
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Fig. 3. Kaplan–Meier plots of death censored long-term graft survival
in patients without acute rejection (AR; —), patients with AR and
Fig. 2. Graft survival (%, y-axis) in patients with acute rejection (AR) average post-AR systolic BP: ,130 mm Hg (s—s), 130 to 140 mm
and a post-AR serum creatinine concentration #2 mg/dl. The X-axis Hg (h—h), 140 to 150 mm Hg (d—d), and .150 mm Hg (j—j).
displays the average systolic blood pressure (BP) following AR (P 5
0.0009, logistic regression).
138), SBP 130 to 140 (1.6 6 0.49, N 5 116), SBP 140 to
150 (1.7 6 0.5, N 5 97), SBP . 150 (1.6 6 0.5, N 5 53,
P 5 0.1, Kruskal–Wallis). When only patients with post-
Cr #2 mg/dl were analyzed, the relationship between
post-BP and graft survival was observed in the following
subgroups of patients: (a) LRD recipients (N 5 115,
P 5 0.01 by univariate logistic regression), (b) CAD
recipients (N 5 356, P 5 0.006), (c) Caucasian recipients
(N 5 384, P 5 0.001), and (d) African American recipi-
ents (N 5 78, P 5 0.01).
In contrast to the findings described above, in patients
without AR, there was no significant correlation between
graft survival and the average BP level during the first-
or second-year post-transplant or during the entire fol-
low-up period (P 5 0.6).
Post-BP levels also correlated with graft survival time.
Figure 3 displays death-censored graft survival plots in
patients without AR or with AR, the latter divided ac-
Fig. 4. Graft survival (y-axis) in patients classified according to thecording to the post-AR systolic BP level (P , 0.0001,
histopathology of acute rejection (AR grade, x-axis). Note that graftCox). Statistical analysis of subgroups of patients defined survival in this analysis includes grafts lost any time post-transplant.
by their average post-BP indicated that graft survival
time was not significantly different between patients
without AR and those with AR and a post-AR average
with renal allograft survival beyond six-months post-systolic BP ,130 mm Hg. However, patients with AR
transplantation. However, when renal allograft survivaland higher levels of post-BP had significantly shorter
any time post-transplant was analyzed, the AR Banffgraft survival than patients without AR.
score correlated with graft survival by univariate analysis
Correlations between acute rejection histopathology (P 5 0.003) but not by a multivariate analysis, which
and graft survival included other correlates of survival such as graft func-
tion, recipient age, and post-BP. Figure 4 displays theAs noted earlier in this article, in patients with one
AR episode, the histopathology of AR did not correlate graft survival at any time post-transplant in four groups
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look for other factors that may account for that variability,
because those additional factors may be amenable to
treatment. Indeed, the demonstration that post-AR BP
correlates with graft survival suggests the possibility that
aggressive antihypertensive therapy may effectively pro-
long graft survival in patients with early AR.
The patient selection strategy used here permitted a
clear separation of the effect of AR number on graft
survival from other factors. However, our attempt to
eliminate the impact of the time of AR on graft survival
failed because even among AR that occurred during the
first-year post-transplant, graft survival is worse the later
the rejection occurs, an observation that is consistent
with previous studies [4, 5]. The reason for this correla-
tion is not entirely clear. However, based on these and
previous results [6], it is reasonable to suggest that this
relationship is due to the fact that the impact of AR on
graft survival is at least in part determined by the func-Fig. 5. Kaplan–Meier plots of death censored graft survival in patients
without AR (- - -), nonvascular AR (—), or vascular AR (—; P , 0.0001 tion of the allograft prior to the AR episode. In support
by Cox analysis). Note that graft survival in this analysis includes grafts of this hypothesis, we show here that the serum creati-
lost any time post-transplant.
nine concentration of pre-AR correlates with long-term
graft survival post-AR. Also consistent with this inter-
pretation is that the pre-Cr concentration is higher in
patients with late AR than in those with early AR.of patients: (a) recipients without AR (N 5 942), (b)
These results strongly suggest that the relationshippatients with nonvascular AR (including Banff grades
between high BP levels and shorter graft survival post-of borderline, I and IIA, N 5 157), (c) patients with
AR is independent of both the race of the recipient andvascular AR (including grades IIB and III, N 5 72), and
the level of graft function. Thus, (a) these correlations(d) patients with infarcts in the biopsy (N 5 16). As can
are statistically independent of each other. (b) The corre-be seen, progressive increases in the severity of AR,
lation between BP and survival was shown in Caucasianshistopathology correlates with progressively worse graft
and African Americans when analyzed separately, andsurvival. In addition, patients with infarcts have signifi-
(c) when only patients with excellent graft function fol-cantly worse prognosis than patients with vascular AR.
lowing AR (post-Cr #2 mg/dl) were selected, BP levelsHowever, the relationship between AR histopathology
continued to be a significant predictor of graft survival.and graft survival is due to differences in the numbers
The impact of BP levels is such that among patients withof graft lost during the first six months following the AR
post-Cr ,2 mg/dl, graft survival was not different inepisode. This is shown in Figure 5. It should be noted that
patients without AR and in patients with AR as long asin this analysis, patients with infarcts were not included
their average post-AR systolic BP was ,130 mm Hg. Itbecause of the small number of patients in this group.
should be emphasized that the calculation of post-ARGraft survival was significantly worse in patients with
BP levels includes the achieved level of BP control, mostvascular rejection than in patients with nonvascular re-
often with treatment, throughout the life of the graft. Injection (P 5 0.05, Cox) because of a higher rate of graft
contrast to these findings, we could not demonstrate alosses during the first six-months post-transplant. Thus,
relationship between BP levels and graft survival in pa-during this period of time, allografts were lost in 5% of
tients without AR, and these results are in disagreementpatients without AR, 8% of patients with nonvascular
with a recently published study [13]. The reasons for theAR, and 19% of patients with vascular AR (P , 0.0001,
discrepancy may include the fact that the study by Opelz,chi-square analysis).
Wujciak, and Ritz, because it included a larger number
of patients, had more statistical power to detect the im-
DISCUSSION pact of BP on survival of grafts without AR, which, as
The present study confirms the strong relationship be- suggested by that study, if present is likely to be mild.
tween AR and renal allograft survival. For example, the However, in addition, in our opinion, that large multicen-
negative effects of AR are such that they cancel the graft ter study did not effectively separate the impact of BP
survival advantage of LRD over CAD transplantation. from the impact of graft function on graft survival. It
However, these results also illustrate the variability of the seems reasonable to postulate that the deleterious effects
of BP on graft survival are particularly pronounced inimpact of AR on graft survival and emphasize the need to
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certain populations of renal allograft recipients, including average systolic BP ,130 mm Hg had a graft survival
patients with AR and African American recipients [2]. time that was not statistically different from that of pa-
The retrospective nature of the present study does not tients without AR. It is significant that only 10% of the
permit a conclusion that elevated BP levels are, at least patients in this study met these criteria. Therefore, the
in part, the cause of the shortened graft survival in pa- majority of patients with AR are at high risk of graft
tients with AR. However, this interpretation of the data loss irrespective of the histopathological score of AR.
is consistent with prospective studies done in patients Furthermore, as can be seen in the graft survival plots,
with native renal diseases in which it has been shown it may take several years to determine the impact of AR
that BP control has impressive beneficial effects slowing on survival.
down the progression of renal insufficiency, particularly
in patients with proteinuria [16, 17]. If these prospective ACKNOWLEDGMENTS
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